Skip to main content

Volume 6 Supplement 3

AIDS Vaccine 2009

P05-05. Enhanced immunogenicity of HIV-1 envelope glycoprotein trimers fused to CD40 ligand

Background

Subunit vaccines are often poor immunogens compared to live-attenuated and whole-inactivated virus vaccines. One reason is the lack of costimulatory signals provided by various components of live-attenuated and whole-inactivated vaccines. Here we improved the immunogenicity of the HIV-1 envelope glycoproteins (Env) by direct fusion to a costimulatory molecule, CD40 ligand (CD40L), which we term 'cis-adjuvant'. The rationale was to target the antigen directly to dendritic cells (DC) and B cells, while at the same time activating these cells.

Methods

Chimeric Env-CD40L containing a stabilized gp140 (SOSIP.R6), a GCN4-based trimerization domain, and the globular domain of human or mouse CD40L, was constructed and expressed transiently expressed in 293T cells. The expression and trimerization was analyzed by SDS-PAGE, BN-PAGE and analytical size exclusion chromatograph. The interaction with ligands and neutralizing antibodies was monitored by immunoprecipitation. The immunomodulatory properties on monocyte-derived immature DCs were tested. After incubation with immature monocyte-derived DC, the upregulation of DC maturation markers was monitored by FACS and the secretion of cytokines was analyzed by ELISA. Mice were immunized with plasmids encoding gp140 or gp140-CD40L via intramuscular or dermal (gene gun) routes and the Env-specific antibody response was followed by ELISA.

Results

The trimeric gp140-CD40L construct interacted with CD4 and CD40 and was recognized by neutralizing antibodies. Moreover, gp140-CD40L was able to activate dendritic cells and induce secretion of cytokines from these cells. Importantly, gp140-CD40L induced ~6-10-fold higher gp120-specific antibody titers than gp140 alone in mice vaccinated via intramuscular or dermal DNA immunization routes.

Conclusion

Fusion to CD40L enhanced the immunogenicity of HIV-1 Env trimers. Antigen targeting via CD40L or other 'cis-adjuvants' may have wider applicability in subunit vaccine development.

Author information

Affiliations

Authors

Corresponding author

Correspondence to RW Sanders.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Melchers, M., Matthews, K., van Montfort, T. et al. P05-05. Enhanced immunogenicity of HIV-1 envelope glycoprotein trimers fused to CD40 ligand. Retrovirology 6, P81 (2009). https://doi.org/10.1186/1742-4690-6-S3-P81

Download citation

Keywords

  • Size Exclusion Chromatograph
  • CD40 Ligand
  • Subunit Vaccine
  • Dendritic Cell Maturation
  • Analytical Size Exclusion Chromatograph